Novartis Investigative Site

Venlo 5912 BL

1 studies enrolling now · 14 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Atherosclerosis, Atherosclerotic Cardiovascular Disease, Cardiovascular Disease, Cardiovascular Disease and Lipoprotein(a), Chronic Heart Failure, Diabetes Mellitus and Heart Failure, Familial Hypercholesterolemia, Heart Failure With Preserved Ejection Fraction, Primary Prevention of Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis

Studies at this site

• An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) — Recruiting now
• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (Core and Extension Phases) — Stopped early